NASDAQ:LMNX - Nasdaq -
36.99
+0.01 (+0.03%)
The current stock price of LMNX is 36.99 null. In the past month the price increased by 0.3%. In the past year, price increased by 1.96%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 24.36 | 203.70B | ||
DHR | DANAHER CORP | 28.07 | 151.18B | ||
A | AGILENT TECHNOLOGIES INC | 25.59 | 38.62B | ||
IQV | IQVIA HOLDINGS INC | 17.15 | 33.64B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 31.26 | 26.91B | ||
WAT | WATERS CORP | 31.58 | 22.26B | ||
ICLR | ICON PLC | 14.39 | 16.63B | ||
WST | WEST PHARMACEUTICAL SERVICES | 31.25 | 15.27B | ||
ILMN | ILLUMINA INC | 38.45 | 14.94B | ||
RVTY | REVVITY INC | 23.23 | 13.85B | ||
AVTR | AVANTOR INC | 17.3 | 11.78B | ||
TEM | TEMPUS AI INC | N/A | 10.72B |
Luminex Corp. develops, manufactures and markets proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The company is headquartered in Austin, Texas and currently employs 1,325 full-time employees. The company went IPO on 2000-03-30. The firm's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The firm has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The firm primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.
Luminex Corp
12212 Technology Blvd, 512-219-8020
Austin TEXAS 78727 US
CEO: Nachum Shamir
Employees: 1325.0
Company Website: http://www.luminexcorp.com/
Phone: 15122494741.0
The current stock price of LMNX is 36.99 null. The price increased by 0.03% in the last trading session.
The exchange symbol of Luminex Corp is LMNX and it is listed on the Nasdaq exchange.
LMNX stock is listed on the Nasdaq exchange.
5 analysts have analysed LMNX and the average price target is 37.74 null. This implies a price increase of 2.03% is expected in the next year compared to the current price of 36.99. Check the Luminex Corp stock analysts ratings, price target forecast and up-and down grades for more detailed information.
Luminex Corp (LMNX) has a market capitalization of 1.75B null. This makes LMNX a Small Cap stock.
Luminex Corp (LMNX) currently has 1325.0 employees.
Luminex Corp (LMNX) has a support level at 36.85 and a resistance level at 37.02. Check the full technical report for a detailed analysis of LMNX support and resistance levels.
The Revenue of Luminex Corp (LMNX) is expected to grow by 16.71% in the next year. Check the estimates tab for more information on the LMNX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
Luminex Corp (LMNX) has a dividend yield of 1.08%. The yearly dividend amount is currently 0.4. Check the full fundamental report for a detailed analysis of LMNX dividend history, reliability and sustainability.
Luminex Corp (LMNX) will report earnings on 2022-03-01, after the market close.
The PE ratio for Luminex Corp (LMNX) is 72.53. This is based on the reported non-GAAP earnings per share of 0.51 and the current share price of 36.99 null. Check the full fundamental report for a full analysis of the valuation metrics for LMNX.
ChartMill assigns a technical rating of 6 / 10 to LMNX. When comparing the yearly performance of all stocks, LMNX is a bad performer in the overall market: 76.4% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to LMNX. LMNX has an average financial health and profitability rating.
Over the last trailing twelve months LMNX reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 563.64% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 5.39% | ||
ROA | 2.88% | ||
ROE | 4.84% | ||
Debt/Equity | 0.52 |
ChartMill assigns a Buy % Consensus number of 60% to LMNX. The Buy consensus is the average rating of analysts ratings from 5 analysts.
For the next year, analysts expect an EPS growth of 159.95% and a revenue growth 16.71% for LMNX